FDA Approved: SORAFENIB — Supplemental Application (Yabao Pharmaceutical Co., Ltd. Beijing)

View source ↗

Summary

FDA approved a supplemental application for Sorafenib by Yabao Pharmaceutical Co., Ltd. Beijing under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

SUPPL AP for SORAFENIB (SORAFENIB)